Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29484533 | 1.00 | TACR1 (0.73) | TACR1TACR3 | |
| SCHEMBL5779778 | 0.89 | TACR1 (0.69) | TACR1TACR3 | |
| SCHEMBL5911802 | 0.89 | TACR1 (0.70) | TACR1TACR3 | |
| SCHEMBL29484509 | 0.88 | TACR1 (0.69) | TACR1TACR3 | |
| SCHEMBL5783406 | 0.88 | TACR1 (0.67) | TACR1TACR3 | |
| SCHEMBL5198319 | 0.88 | TACR1 (0.69) | TACR1TACR3 | |
| SCHEMBL5199251 | 0.88 | TACR1 (0.62) | TACR1TACR3 | |
| SCHEMBL6796494 | 0.86 | TACR1 (0.64) | TACR1TACR3 | |
| SCHEMBL5782942 | 0.85 | TACR1 (0.62) | TACR1TACR3 | |
| SCHEMBL337184 | 0.85 | TACR1 (0.74) | TACR1TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1776117-A1 | DUAL NK1/NK3 ANTAGONISTS AGAINST SCHIZOPHRENIA | F.HOFFMANN-LA ROCHE AG (CH) | 2007-04-25 | — | — | EP | claimed |
| US-20060030600-A1 | Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | US | claimed |
| WO-2006013050-A1 | DUAL NK1/NK3 ANTAGONISTS AGAINST SCHIZOPHRENIA | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | WO | claimed |
| US-20260014166-A1 | NOVEL USES OF DUAL NK-1 /NK-3 RECEPTOR ANTAGONISTS FOR TREATING SEX-HORMONE DISEASES | KaNDy Therapeutics Limited (GB) | 2026-01-15 | — | — | US | disclosed |
| CN-114306347-A | Dual NK-1/NK-3 receptor antagonists for the treatment of sex hormone dependent diseases | 康堤医疗有限公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-114306335-A | Dual NK-1/NK-3 receptor antagonists for the treatment of sex hormone dependent diseases | 康堤医疗有限公司 | 2022-04-12 | — | — | CN | disclosed |
| CN-114272242-A | Dual NK-1/NK-3 receptor antagonists for the treatment of sex hormone dependent diseases | 康堤医疗有限公司 | 2022-04-05 | — | — | CN | disclosed |
| US-20210236506-A1 | NOVEL USES | KaNDy Therapeutics Limited (GB) | 2021-08-05 | — | — | US | disclosed |
| US-20210128574-A1 | NOVEL USES | KaNDy Therapeutics Limited (GB) | 2021-05-06 | — | — | US | disclosed |
| EP-3574907-A1 | AN NK-1/NK-3 RECEPTOR ANTAGONIST FOR THE TREATMENT OF SEX-HORMONE-DEPENDENT DISEASES | NeRRe Therapeutics Limited (GB) | 2019-12-04 | — | — | EP | disclosed |
| US-10195205-B2 | Uses of dual NK1/NK3 receptor antagonists for treating sex-hormone diseases | NERRE THERAPEUTICS LIMITED (GB) | 2019-02-05 | — | — | US | disclosed |
| EP-3297631-A1 | DUAL NK-1/NK-3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SEX-HORMONE-DEPENDENT DISEASES | NeRRe Therapeutics Limited (GB) | 2018-03-28 | — | — | EP | disclosed |
| WO-2016184829-A1 | DUAL NK-1/NK-3 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF SEX-HORMONE-DEPENDENT DISEASES | NERRE THERAPEUTICS LIMITED (GB) | 2016-11-24 | — | — | WO | disclosed |
| US-20160339037-A1 | Novel Uses | KaNDy Therapeutics Limited (GB) | 2016-11-24 | — | — | US | disclosed |
| EP-1776117-A1 | DUAL NK1/NK3 ANTAGONISTS AGAINST SCHIZOPHRENIA | F.HOFFMANN-LA ROCHE AG (CH) | 2007-04-25 | — | — | EP | disclosed |
| US-20060030600-A1 | Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | US | disclosed |
| WO-2006013050-A1 | DUAL NK1/NK3 ANTAGONISTS AGAINST SCHIZOPHRENIA | F. HOFFMANN-LA ROCHE AG (CH) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210236506-A1 | NOVEL USES | KLKB1, KLK3, KLK1 | TACR1 20/4885TACR3 22/4885 |
| US-20260014166-A1 | NOVEL USES OF DUAL NK-1 /NK-3 RECEPTOR ANTAGONISTS FOR TREATING SEX-HORMONE DISEASES | KISS1R, GPER1, FSHR | TACR1 65/4885TACR3 191/4885 |
| US-10195205-B2 | Uses of dual NK1/NK3 receptor antagonists for treating sex-hormone diseases | KISS1R, KLKB1, KLK3 | TACR1 11/4885TACR3 35/4885 |
| US-20160339037-A1 | Novel Uses | KLKB1, KLK3, KLK1 | TACR1 20/4885TACR3 22/4885 |
| US-20060030600-A1 | Dual NK1/NK3 receptor antagonists for the treatment of schizophrenia | TACR2, TACR1, TAC3 | TACR1 2/4885TACR3 6/4885 |
| US-20210128574-A1 | NOVEL USES | KLKB1, KLK3, KLK1 | TACR1 20/4885TACR3 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.